Extract
Covidien Reports Second-Quarter 2009 Results.
* Second-quarter net sales up 11%, led by increases in Pharmaceutical Products
* Second-quarter diluted GAAP earnings per share from continuing operations were $0.34 * Excluding Oxy ER and specified items, adjusted diluted earnings per share from continuing operations were $0.69; including Oxy ER, adjusted diluted earnings per share from continuing operations were $1.07 DUBLIN -- Covidien Ltd. (NYSE: COV; BSX: COV) today reported results for the second quarter of fiscal 2009 (January - March 2009). Second-quarter results reflected strong growth in Pharmaceutical Products, primarily due to oxycodone hydrochloride extended-release tablets (Oxy ER). Excluding Oxy ER, Covidien registered a good quarterly performance in its base business. Second-quarter net sales rose 11% to $2.7 billion from $2.4 billion a year ago, with unfavorable for...See the full content of this document
Sponsored links
